Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
about
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15Regulating the immune system via IL-15 transpresentationCrystal Structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentationHarnessing the Microbiome to Enhance Cancer ImmunotherapyThe shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyChanges in IL-15 expression and death-receptor apoptotic signaling in rat gastrocnemius muscle with aging and life-long calorie restrictionIntramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cellsEngulfing tumors with synthetic extracellular matrices for cancer immunotherapyIL-15Rα deficiency in skeletal muscle alters respiratory function and the proteome of mitochondrial subpopulations independent of changes to the mitochondrial genomeLoss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles.Biopolymer implants enhance the efficacy of adoptive T-cell therapy.Novel human interleukin-15 agonistsNew insights into the regulation of T cells by gamma(c) family cytokinesSerum and muscle interleukin-15 levels decrease in aging mice: correlation with declines in soluble interleukin-15 receptor alpha expressionInterleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cellsNaive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cellsMemory-like CD8+ T cells generated during homeostatic proliferation defer to antigen-experienced memory cells.Role of NK cells in host defense against pulmonary type A Francisella tularensis infectionA defective Il15 allele underlies the deficiency in natural killer cell activity in nonobese diabetic mice.Loss of cytotoxicity and gain of cytokine production in murine tumor-activated NK cells.IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by Leishmania infantum in vivo.Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.STAT5 is critical to maintain effector CD8+ T cell responses.Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activityExpression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cisTargeting CD8+ T-cell tolerance for cancer immunotherapy.Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in miceIL-2 complex treatment can protect naive mice from bacterial and viral infection.Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation.Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapyIL-15 Enables Septic Shock by Maintaining NK Cell Integrity and Function.Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune moleculesA role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection.IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo.Induction and function of virus-specific CD4+ T cell responses.Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.
P2860
Q24301975-71C4D20A-D9DB-45BB-8232-8CF134E5E38EQ26825247-B1BB2A23-CA82-46AB-916E-F82B2E729190Q27648832-2FB0D219-5BB5-45AF-970F-2904D7DBFAA9Q28088598-44AF73DD-75F0-4765-A2EF-4423F02B8D4AQ28088784-DC9A8783-6660-4A3D-8C12-7D7F8126D79CQ28569873-6761825F-DE1A-4C34-8F09-AEA5371D61CAQ28652428-F3BE5264-5B09-40B6-890E-80B4B44F8010Q28749647-ED8AFFD3-8750-426A-AFA6-501E9D9005BBQ29248840-F0E58775-97E1-48BA-BFFC-E1BFA6FD3716Q30503154-04692079-1E0B-44F9-AA8E-176DF5B1FBB4Q30614247-AF5B7148-B6EA-4C3D-8677-9ED98187DD97Q33623266-F43C52AB-156B-4F56-84BE-D86758FC55BAQ33623326-0CBDC88D-397C-44A0-BE77-C1E644030FD0Q33624343-37C99EB4-81C5-4422-8486-370B9629931BQ33638464-8244646A-7F08-421C-9E8A-06804EFCA746Q33705698-74A06D60-372B-450D-AC65-C274248C8AB1Q33730129-62E24D70-F766-4BBF-AB1B-25ADF2B04326Q33760403-21F115FB-1BDE-4277-9C30-5D488C651B9DQ33767707-D07FBB67-872E-44BD-9106-34D3FE3C9F90Q33835506-9BC35CE9-FE0E-467C-BBC2-24FB7A649BDFQ33871500-F6D0E039-BFBF-4542-8E6D-2D5820D12394Q33927289-77B60625-22C2-4612-94EA-EB79C64285F3Q34015437-138DF991-E740-466B-877A-C07BABA3F575Q34017578-8F07CC98-1A95-40FE-9816-D54416D87C51Q34112602-EDB6E6C5-37FB-41B3-B062-C89BAE81F6D8Q34120958-090AFE8B-A99E-4DCA-B840-3BEFCA2E4009Q34346687-21DA878D-A869-49A2-8B89-2A8ECDC3579FQ34351517-0FBFBE1F-9CC5-4102-9B94-B99053455B61Q34415755-052137B4-4D7F-4AB0-889E-E9D308AF42D0Q34432692-63947861-CD91-4BF3-9605-23D1652B5658Q34451078-397D15C0-0C24-49D0-833F-E39C9CFC22A8Q34470815-EC8EAA87-6715-4331-A558-79AFB8106540Q34470833-E6417BA7-F013-4B0A-A439-CAAED1303644Q34533728-DAD2FA02-98E8-487D-A91E-AA8DBEE06997Q34548214-A66D8D14-9282-4995-A49D-15AB7BDD6252Q34626998-A792E6BB-C903-4927-AB53-36B74AD1CB4FQ34632137-5BA39E62-91B9-46D2-A8F1-24833ADEDEDBQ34794353-2B6A0E13-CCAE-474C-B552-93DEA94950FEQ34856857-C5E91AEE-FB0F-4171-B563-347DD97ABF09Q34936507-8F90C4D1-127D-4F4C-BBD9-977C85FEE63F
P2860
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@ast
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@en
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@nl
type
label
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@ast
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@en
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@nl
prefLabel
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@ast
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@en
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@nl
P2093
P2860
P356
P1476
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
@en
P2093
Charles D Surh
Jae-Ho Cho
Jared F Purton
Marek Kovar
Mark P Rubinstein
P2860
P304
P356
10.1073/PNAS.0600240103
P407
P577
2006-06-06T00:00:00Z